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Specificity of histological markers 
of long-term CNI nephrotoxicity in 
kidney transplant recipients under 
low-dose cyclosporine therapy
Snanoudj et al., Am J Transplant 2011; 11: 2635–2646; doi:10.1111/j.1600-
6143.2011.03718.x
With the ongoing discussion about the potential benefits for 
renal transplants of immunosuppressive regimens that do 
not contain calcineurin inhibitors (CNIs), the issue of the 
specificity of chronic histological lesions induced by CNIs is 
of considerable interest. Few studies have directly compared 
long-term lesions in renal transplant patients who received 
this treatment versus those who did not. Snanoudj et al. there-
fore conducted a retrospective study of 141 kidney transplant 
recipients treated with (n = 48) or without (n = 93) cyclo-
sporine (CsA) to compare the histological lesions observed 
at 3-month, 24-month, and 10-year protocol biopsies. All 
chronic lesions consisting of glomerulosclerosis, interstitial 
fibrosis, tubular atrophy, arteriolar hyalinosis, or fibrointimal 
thickening progressed by a comparable degree in both groups, 
although significantly more in the CsA group. Ten-year biopsy 
results showed that 92% of patients in the CsA-treated group 
and 65% in the control group had arteriolar hyalinosis lesions. 
With regard to muscular arteriolar hyaline deposits that are 
supposedly more specific to CsA arteriolopathy, these lesions 
occurred in 68% of CsA patients as well as in 28% of patients 
who had never received CsA.
Thus, histological lesions commonly attributed to CsA 
nephrotoxicity are not sufficiently specific to definitively diag-
nose CNI nephrotoxicity—important to keep in mind when 
using histopathological evaluation in studies comparing vari-
ous immunosuppressive regimens.
Detlef Schlöndorff
The endothelium-derived 
hyperpolarizing factor H2S 
regulates potassium channels
Mustafa et al., Circ Res 2011; 109: 1259–1268; doi:10.1161/
CIRCRESAHA.111.240242
The identification of nitric oxide (NO) as a mediator of 
endothelium-dependent vasorelaxation greatly expanded 
the understanding of vascular homeostasis. NO acts both by 
increasing cyclic guanosine monophosphate levels and by 
regulating calcium disposition and sensitivity. However, NO 
does not significantly affect membrane potential, and vas-
cular tone is greatly influenced by endothelium-dependent 
hyperpolarization. Numerous substances have been advanced 
as putative endothelium-derived hyperpolarizing factors 
(EDHFs), and it has even been suggested that EDHF action 
may be mediated through direct coupling between endothelial 
and smooth muscle cells. It was recently found that hydrogen 
sulfide (H2S) is a major endothelium-derived relaxing factor. 
H2S forms in vascular endothelial cells from cysteine by cys-
tathionine g-lyase (CSE), a calcium/calmodulin-dependent 
enzyme. CSE-deleted mice have hypertension and markedly 
reduced acetylcholine-mediated vasorelaxation. The role of 
two other enzymes able to generate H2S in various tissues 
remains undefined. To identify the mechanism whereby 
H2S induces vasorelaxation, Mustafa et al. used a variety of 
approaches and confirmed the previous observation that, 
particularly in resistance arteries but much less so in large 
arteries, cholinergic relaxation was in great part NO-inde-
pendent, and that it was reduced by about 60% in arteries of 
CSE-deleted mice. In addition, they found that cholinergic 
relaxation was associated with pronounced hyperpolarization, 
and that in CSE-deleted animals, hyperpolarization was vir-
tually abolished. The vasorelaxing and hyperpolarizing effect 
of H2S involved potassium channels, as they were blocked 
by 30 mmol/l KCl and appropriate pharmacological probes. 
Sulfhydration appears to be a principal means whereby H2S 
signals, and Mustafa et al. found that both the Kir6.1 subunit 
of adenosine triphosphate (ATP)-sensitive K+ channels and 
IKca channels were sulfhydrated. Sulfhydration augmented 
ATP-sensitive potassium channel activity by reducing Kir6.1–
ATP binding and enhancing Kir6.1–PIP2 binding (Figure). 
The study also makes apparent that, unlike NO, which signals 
primarily in larger conductance vessels, H2S activity is nota-
bly more active in smaller vascular beds, the resistance blood 
vessels that determine blood pressure: H2S activity was more 
prominent in the mesenteric artery than in the aorta, which 
displayed more prominent NO-mediated relaxation.
In summary, this study shows that H2S is a major EDHF 
of the blood vessels that regulate blood pressure and estab-
lishes a novel mechanism of action for vasodilation. It suggests 
that drugs altering CSE activity or H2S-mediated channel 
sulfhydration may be beneficial in treating vascular diseases 
including hypertension.
Juan Oliver
Sulfhydration augments ATP-sensitive potassium channel activity. 
(a) Model of Kir6.1 with cysteine-43 highlighted in yellow as well as ATP-
interacting residues highlighted in violet. (b) Model of Kir6.1 with cysteine-43 
highlighted in yellow and PIP2-interacting residues in slate blue.
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Associations of ABCB1 
3435C>T and IL-10 –1082G>A 
polymorphisms with long-term 
sirolimus dose requirements in 
renal transplant patients
Sam et al., Transplantation 2011; 92: 1342–1347; doi:10.1097/
TP.0b013e3182384ae2
Therapeutic drug monitoring of sirolimus (SRL), a potent 
immunosuppressant, is necessary in view of the fact that 
steady-state SRL through concentrations less than 5 ng/ml 
and more than 15 ng/ml was associated with the occurrence 
of acute rejection episodes and adverse reactions such as leuko-
penia and thrombocytopenia, respectively. The gene encoding 
the drug efflux pump P-glycoprotein (ABCB1) and the genes 
encoding the hepatic and intestinal cytochrome P450 family 
members CYP3A4 and CYP3A5, which are further under the 
influence of cytokine concentrations, are important determi-
nants of SRL bioavailability and metabolism. Sam et al. per-
formed a retrospective study determining the associations 
of ATP-binding cassette, subfamily B, member 1 (ABCB1) 
1236C>T, 2677 G>T/A, and 3435C>T; cytochrome P450, fam-
ily 3, subfamily A, polypeptide 4 (CYP3A4) –392A>G; cyto-
chrome P450, family 3, subfamily A, polypeptide 5 (CYP3A5) 
6986A>G and 14690G>A; interleukin-10 (IL-10) –1082G>A; 
and tumor necrosis factor (TNF) –308G>A polymorphisms 
with SRL dose-adjusted, weight-normalized trough concentra-
tions (C/D) at 7 days and at 1, 3, 6, and 12 months after initia-
tion of SRL. Genotypes for 86 renal transplant patients who 
received SRL-based maintenance immunosuppressive therapy 
were determined by PCR followed by chip-based mass spec-
trometry. The changes of log-transformed C/D over the days 
post-transplantation were analyzed by a linear mixed-effects 
model, with adjustments for body mass index and weight-
normalized doses of tacrolimus, prednisone, clotrimazole, 
and statins. ABCB1 3435C>T and IL-10 –1082G>A were sig-
nificantly associated with log C/D. Mean SRL C/D was 48% 
higher in patients with ABCB1 3435CT/TT genotype than in 
those with 3435CC genotype and was 24% higher in IL-10 
–1082GG compared with –1082AG/AA. ABCB1 3435C>T 
and IL-10 –1082G>A were significantly associated with long-
term SRL dose requirements. The finding in this study that 
IL-10 –1082GG homozygotes had higher SRL concentration/
dose ratios, consistent with enhanced IL-10 expression, lead-
ing to lowered CYP3A activity and reduced SRL metabolism 
in patients with this genotype is of high interest. This result 
seems to agree with the previous finding that carrying IL-10 
–1082A is a risk factor for steroid dependency at 1 year after 
transplantation.
Pharmacogenetics plays a significant role in SRL dosing 
and may be useful in therapeutic monitoring of SRL in renal 
transplantation. Although controversies still exist, this paper 
moves a step further in the unraveling of the complexity of 
the many factors that determine the final bioavailability and 
metabolism of immunosuppressive drugs.
Marc De Broe
Effect of two intensive statin 
regimens on progression of 
coronary disease
Nicholls et al., N Engl J Med 2011; 365: 2078–2087; doi:10.1056/
NEJMoa1110874#t=article
Statins have been shown to reduce adverse cardiovascular out-
comes in patients with heart disease. In parallel imaging studies, 
statins also have been shown to stabilize and even bring about 
regression of specific atherosclerotic plaques.1,2 Nicholls et al. 
compared the respective abilities of rosuvastatin and atorvasta-
tin to affect the atherosclerotic plaque burden among people with 
documented coronary artery disease. Eligible subjects, aged 18–75 
years and with at least one vessel with 20% stenosis on clinically 
indicated coronary angiography and a target vessel for imag-
ing with less than 50% obstruction, were randomized to receive 
atorvastatin (80 mg daily) or rosuvastatin (40 mg daily) for 104 
weeks. Intravascular ultrasonography was performed at baseline 
and after 104 weeks of therapy. One thousand three hundred 
eighty-five patients were randomly assigned to full-dose treat-
ment: 691 to atorvastatin and 694 to rosuvastatin. Seventy-five 
percent (519 in the atorvastatin group and 520 in the rosuvastatin 
group) completed the study and had follow-up study for com-
parison. Percent atheroma volume (PAV), the primary efficacy 
end point, decreased by 0.99% (95% confidence interval (CI), 
−1.19 to −0.63) with atorvastatin and by 1.22% (95% CI, −1.52 to 
−0.90) with rosuvastatin. Total atheroma volume (TAV), a second-
ary end point, decreased by 6.39 mm3 (95% CI, −7.52 to −5.12) 
with rosuvastatin as compared with −4.42 mm3 (95% CI, −5.98 to 
−3.26) with atorvastatin. The proportions of people in each treat-
ment group who demonstrated regression in their atherosclerotic 
lesions were similar (63.2% in the atorvastatin and 68.5% in the 
rosuvastatin group for PAV, and 64.7% in the atorvastatin and 
71.3% in the rosuvastatin group for TAV). Interactions between 
treatment groups revealed a larger association between rosuva-
statin and the outcomes among women as compared with men 
and among people with higher baseline high-density lipoprotein 
and people with higher baseline low-density lipoprotein. Trials 
of statin treatment have failed to demonstrate a benefit for end-
stage renal disease patients3,4 but did show improved outcomes 
in chronic kidney disease patients.5
Given the consistency of this study in terms of disease regres-
sion, the mechanism of the failure of statins in end-stage renal 
disease patients should be re-explored. If disease burden is too 
great or plaques are otherwise resistant, we still may be able to 
show a benefit of these agents to our populations through re-
examination of the dosing or strategies for administration.
Lynda Szczech
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